E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To evaluate safety and tolerability of three lots of Chiron’s cell-derived influenza subunit vaccine as compared to a conventional egg-derived control vaccine, three weeks after a single 0.5 mL intramuscular (IM) injection. To collect additional safety data such as serious adverse events, adverse events necessitating a physician’s visit and/or resulting in premature subject’s withdrawal from study for approximately six months after vaccination to be included in an addendum to the final study report.
|
|
E.2.2 | Secondary objectives of the trial |
To evaluate immunogenicity of the two vaccines and of each vaccine lot three weeks after a single 0.5 mL IM injection, by the measurement of strain-specific hemagglutination inhibition (HI) tests according to the current CHMP criteria (CPMP/BWP/214/96), as described below. For the HI test the measures of immunogenicity for each antigen are: - geometric mean titer (GMT) on study day 1 (Visit 1) and on study day 22 (Visit 2) - study day 22/study day 1 GMT ratio (GMR) - percentage of subjects achieving seroconversion* or significant increase in antibody titer** - percentage of subjects achieving an HI titer of ≥ 40 on study day 1 and study day 22 Of Note: *Seroconversion is defined as negative pre-vaccination serum (<10) / post-vaccination titer ≥40. **Significant increase in antibody titer is defined as at least a fourfold increase from non-negative pre-vaccination serum (≥10)
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
Inclusion criteria: 1) 18 to <61 years of age 2) mentally competent to understand the nature, the scope and the consequences of the study 3) able and willing to give written informed consent prior to study entry 4) in good health as determined by: a. medical history, b. physical examination, c. clinical judgment of the Investigator. |
|
E.4 | Principal exclusion criteria |
Exclusion criteria: 1) unwilling or unable to give written informed consent to participate in the study 2) participation in another clinical trial of an investigational agent within 90 days prior to Visit 1 and throughout the entire study 3) currently experiencing an acute infectious disease 4) any serious disease, such as, for example: a. cancer, b. autoimmune disease (including rheumatoid arthritis), c. advanced arteriosclerotic disease or complicated diabetes mellitus, d. chronic obstructive pulmonary disease (COPD) requiring oxygen therapy, e. acute or progressive hepatic disease, f. acute or progressive renal disease, g. congestive heart failure 5) surgery planned during the study period 6) bleeding diathesis 7) history of hypersensitivity to any component of the study medication or chemically related substances 8) history of any anaphylaxis, serious vaccine reactions, or allergy to any of the vaccine component 9) known or suspected impairment/alteration of immune function, for example resulting from: a. receipt of immunosuppressive therapy (any corticosteroid therapy or cancer chemotherapy), b. receipt of immunostimulants, c. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivates within 3 months prior to Visit 1 or planned during the full length of the study, d. high risk for developing an immunocompromising disease 10) history of drug or alcohol abuse 11) laboratory-confirmed influenza disease within 6 months prior to Visit 1 12) receipt of influenza vaccine within 6 months prior to Visit 1 13) receipt of another vaccine within 60 days prior to Visit 1, or planned vaccination within 3 weeks following study vaccination 14) any acute respiratory disease or infections requiring systemic antibiotic or antiviral therapy (chronic antibiotic therapy for urinary tract prophylaxis is acceptable) or experienced fever (i.e., axillary temperature ≥ 38°C) within 5 days prior to Visit 1 15) if female, pregnant or breastfeeding 16) if female, refusal to use a reliable contraceptive method during the three weeks following vaccination 17) planned relocation abroad during the study period 18) any condition that, in the opinion of the Investigator, might interfere with the evaluation of the study objectives. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
CRITERIA FOR ASSESSING SAFETY OBJECTIVES: There are no established standard CHMP criteria to assess safety. However, safety will be assessed considering the number of subjects who report local and systemic reactions, as well as the number of subjects who report any adverse event, serious adverse events and/or adverse events resulting in the premature withdrawal from the study, per vaccination group.
CRITERIA FOR ASSESSING IMMUNOGENICITY OBJECTIVES: The following serological assessments (CPMP/BWP/2490/00, CPMP/BWP/214/96) will be considered for the two vaccines and for each vaccine lot, and for each strain, in adult subjects aged 18 to < 61 years at 21 days after vaccination: - number of seroconversions or significant increase in anti-hemagglutinin antibody titer > 40% - mean geometric increase > 2.5 - proportion of subjects achieving an HI titer ≥ 40 should be > 70% All immunogenicity analyses will be repeated for the subset of subjects who are not protected pre-vaccination (< 40).
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 0 |
E.8.9.1 | In the Member State concerned months | 8 |
E.8.9.1 | In the Member State concerned days | |